FLOW found a lower risk of its composite kidney and cardiovascular endpoint with semaglutide in adults with type 2 diabetes and chronic kidney disease. The result is stronger than a weight-loss extrapolation, but it does not describe everyone taking semaglutide.
What the trial actually counted
FLOW randomized 3,533 people with type 2 diabetes and chronic kidney disease to semaglutide or placebo, alongside standard care. Over a median 3.4 years, the primary endpoint occurred in 331 versus 410 participants; the hazard ratio was 0.76. The trial was funded by Novo Nordisk.[1]
The endpoint combined kidney failure, a sustained large decline in estimated filtration, or death from kidney or cardiovascular causes. Combining events lets a trial answer a broader risk question. It also means the headline is not a count of kidney transplants alone or proof that every component improved equally.
| Measure | Meaning |
|---|---|
| 331 versus 410 | Participants with a first primary endpoint event in the two groups. |
| Hazard ratio 0.76 | About 24% lower relative hazard over follow-up. |
| Composite endpoint | Several specified kidney and cardiovascular outcomes counted together. |
The 24% figure is not a 24-percentage-point reduction in everyone’s chance of kidney failure. Relative measures need a starting risk and a period of observation before they can be translated into an individual expectation. A person with a different kidney condition may have a very different starting risk.
Why this is different from a weight-loss study
A weight-loss trial primarily measures the change in body weight. FLOW was designed around serious kidney and cardiovascular outcomes. That difference makes it relevant to a question that a before-and-after weight chart cannot answer. The value of a medicine can depend on which health problem is being treated, not only how much weight it changes.
Participants had both diabetes and chronic kidney disease, and the tested regimen used weekly semaglutide 1 mg. Those details belong alongside the result; the paper is not a randomized comparison of every semaglutide brand or compounded preparation.[1]
Current Ozempic labeling includes reducing sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This is a specific approved-product indication, not a blanket claim for every semaglutide preparation.[2]
It is also not a head-to-head trial against tirzepatide. Someone choosing between products cannot take FLOW’s hazard ratio, place it beside an unrelated weight-loss percentage and declare one universal winner. The endpoints, populations and comparison groups are doing different jobs.
What a good follow-up conversation covers
The most useful discussion starts with the existing kidney diagnosis and treatment plan. Which clinician holds the recent kidney results? Who manages diabetes medicines? Who reviews new symptoms or changes in intake? These questions matter because a remote weight service may otherwise see only a small part of the patient’s care.
The study does not give a consumer a self-directed medication adjustment plan. Its practical contribution is a reason to bring a specific trial and a specific condition to the treating team. That is more useful than asking whether an ingredient is broadly “kidney safe” without naming the diagnosis or the other medicines involved.
Keep a distinction between a benefit observed over years and the need to manage problems during treatment. A favorable long-term outcome result does not mean every short-term symptom can be ignored. Likewise, an individual adverse effect does not erase the population-level evidence; it changes the clinical decision for that individual.
Price the care pathway that matches the diagnosis
For a person with diabetes and kidney disease, a cheap weight-only subscription may be a poor comparison with an integrated clinical service. Look at whether records can be transferred, whether the prescriber can coordinate with existing specialists and how medication changes are communicated. These are concrete service features that deserve space beside the monthly price.
Our Teladoc review explains why benefit eligibility matters, and the Virta review examines a diabetes-centered care model. Neither review establishes personal eligibility or replaces a treating clinician’s assessment. The provider shortlist helps distinguish broader care from prescription-focused services.
Ask the insurer about the exact prescribed product and diagnosis rather than presenting a generic request for a GLP-1. Keep the medication copayment separate from consultations and any independently billed monitoring. Our quote checklist can make those categories explicit.
The financial advantage of an existing covered practice may be continuity rather than a visibly lower advertised drug price. If a new subscription duplicates care already available through the plan, it should offer a clear additional service to justify that extra recurring charge.